Retroperitoneal fibrosis is a rare condition where scar-like tissue develops behind the abdominal cavity, potentially causing serious complications if left untreated. Treatment focuses on reducing inflammation, preserving kidney function, and preventing organ damage through a combination of medications and, when necessary, surgical procedures.

Guiding Patients Through Treatment Options

When someone receives a diagnosis of retroperitoneal fibrosis, also known as Ormond’s disease, the primary goals of treatment become clear: control symptoms, slow down the scarring process, protect kidney function, and prevent life-threatening complications. This rare condition develops when fibrous tissue grows abnormally in the space behind the abdominal organs, often squeezing vital structures like the tubes that carry urine from the kidneys to the bladder, called ureters.^[1]

Treatment decisions depend heavily on how advanced the disease is when diagnosed, which organs are affected, and how each patient responds to initial therapies. There is no single treatment that works for everyone. Instead, doctors typically combine different approaches, tailoring the plan to each person’s specific situation. Some patients need immediate intervention to relieve blocked urine flow, while others may start with medications to calm inflammation and stop the tissue from growing further.^[2]

Most cases of retroperitoneal fibrosis have no known cause, making them what doctors call idiopathic. However, about one-third of cases develop secondary to other conditions such as cancer, certain medications, infections like tuberculosis, or previous radiation therapy. Understanding whether the condition is idiopathic or secondary helps guide treatment choices, as secondary cases may improve when the underlying cause is addressed.^[2]

Modern medicine offers both established treatments approved by medical societies and newer therapies being tested in research studies. While standard treatments have decades of experience behind them, ongoing clinical trials continue to explore innovative approaches that may offer better outcomes with fewer side effects. The landscape of treatment is evolving, giving patients and their doctors more options to consider.^[11]

Standard Medical Treatment Approaches

The cornerstone of medical treatment for retroperitoneal fibrosis involves medications that dampen the body’s inflammatory response. Because this condition is believed to have an autoimmune origin in many cases, treatments focus on calming the immune system’s overactivity that drives tissue scarring.^[2]

Corticosteroid Therapy

Corticosteroids, particularly prednisolone, have been the first-line treatment since 1958, when they were first reported to help patients with retroperitoneal fibrosis. These powerful anti-inflammatory medications work by suppressing the production of substances called cytokines that contribute to inflammation, and by preventing the formation of collagen, the main protein in scar tissue.^[9]

A standard treatment protocol typically starts with prednisolone at doses between 40 to 60 milligrams per day. Over the following two to three months, doctors gradually reduce the dose to about 10 milligrams daily, continuing treatment for anywhere from 12 to 24 months before attempting to stop the medication. This gradual reduction is important because stopping too quickly can cause the disease to flare up again.^[9]

Research analyzing 147 patients treated with steroids showed good results in about 83 percent of cases. The fibrotic mass often shrinks by around 50 percent in up to 95 percent of patients. However, about 16 percent of patients experience recurrence, most commonly within the first year after treatment. Many of these recurrences respond well when steroid treatment is restarted.^[9][14]

Other Immunosuppressive Medications

To reduce the need for high-dose, long-term steroids, doctors often add other immune-suppressing medications. Azathioprine is commonly used alongside corticosteroids, particularly in patients showing signs of active inflammation such as elevated markers in blood tests. This combination approach can be especially useful when the standard steroid doses alone prove insufficient or cause intolerable side effects.^[9]

Mycophenolate mofetil, often abbreviated as MMF, represents another option that some medical centers report gives better outcomes, though findings vary between different research reports. Other medications that have been tried include methotrexate, cyclophosphamide, and cyclosporine, though these are generally reserved for cases that don’t respond to first-line treatments.^[11][14]

Tamoxifen and Hormonal Approaches

Tamoxifen, a medication better known for treating breast cancer, has shown promise in managing retroperitoneal fibrosis. This selective estrogen receptor modulator appears to help in various small studies, though researchers don’t fully understand exactly how it works for this condition. Some medical centers use tamoxifen either alone or combined with other medications, particularly when patients cannot tolerate steroids or need to avoid their side effects.^[6][9]

Other hormonal medications like medroxyprogesterone acetate and progesterone have also been explored experimentally, though they are used less commonly than tamoxifen.^[9]

Duration and Monitoring of Medical Treatment

Treatment typically continues for 12 to 24 months, though some patients need longer courses. During treatment, doctors monitor patients closely with regular blood tests to check kidney function and inflammatory markers, along with imaging studies like CT scans or MRI to see if the fibrous tissue is shrinking. These follow-up tests help doctors determine whether treatment is working and when it might be safe to reduce or stop medications.^[14]

A comprehensive analysis of multiple studies found that across different treatment approaches, about 80 to 98 percent of patients showed regression of the fibrotic tissue. However, the relapse rate across studies averaged about 18 percent, highlighting the importance of long-term monitoring even after successful initial treatment.^[11]

Surgical Treatment Options

Surgery plays an important role in managing retroperitoneal fibrosis, particularly when the ureters become severely blocked, threatening kidney function. The most urgent surgical need is to restore urine flow from the kidneys. Without intervention, blocked ureters can cause urine to back up, leading to kidney swelling and potentially permanent kidney damage or failure.^[1]

Ureter Decompression Procedures

When ureters become obstructed, doctors can insert a thin, flexible tube called a double J stent (or DJ stent) through the bladder up into the ureter to hold it open and allow urine to drain. Alternatively, they may place a tube called a percutaneous nephrostomy (PCN) directly through the skin into the kidney to drain urine externally. These procedures provide immediate relief while giving time for medications to reduce the fibrous tissue pressing on the ureters.^[11]

Many patients who receive stents can eventually have them removed once medical treatment shrinks the fibrotic mass enough to relieve the pressure on the ureters. Research shows that combining stent placement with medical therapy reduces the rate of ureter re-narrowing from 48 percent down to 10 percent compared to surgery alone.^[9]

Ureterolysis

Ureterolysis is a surgical procedure where surgeons carefully free the ureters from the surrounding fibrous tissue that’s compressing them. During this operation, the ureters are separated from the scar tissue and may be moved to a different position where they’re less likely to become entrapped again. Sometimes surgeons wrap the freed ureters in a protective layer of tissue from elsewhere in the abdomen to prevent them from becoming stuck again.^[14]

This procedure can be performed through traditional open surgery or using minimally invasive techniques like laparoscopy, where small incisions and specialized instruments allow surgeons to work through tiny openings. The choice of technique depends on the extent of disease, the surgeon’s expertise, and the patient’s overall health.^[14]

When Surgery Is Necessary

Surgery becomes particularly important when severe urinary tract obstruction threatens kidney function, when medications aren’t working effectively, or when there’s concern that cancer might be causing or mimicking retroperitoneal fibrosis. In some cases, surgeons need to take tissue samples, called biopsies, to rule out malignancy, especially if the pattern of disease seems unusual or doesn’t respond to standard treatments.^[2]

Innovative Treatments Being Studied in Clinical Trials

While standard treatments have proven effective for many patients, researchers continue exploring new approaches that might offer better results with fewer side effects. Clinical trials represent the bridge between promising laboratory discoveries and treatments that doctors can confidently use in everyday practice. These studies carefully evaluate both the safety and effectiveness of new therapies under controlled conditions.^[2]

Rituximab: Targeting B Cells

Rituximab represents one of the most promising newer treatments being studied for retroperitoneal fibrosis. This medication is what scientists call a monoclonal antibody—a laboratory-made protein designed to target specific cells in the immune system. Rituximab specifically targets B cells, which are white blood cells that produce antibodies and play a role in autoimmune diseases.^[9]

The rationale for using rituximab stems from growing evidence that retroperitoneal fibrosis involves abnormal immune system activity. By depleting B cells temporarily, rituximab may interrupt the inflammatory cascade that drives tissue scarring. Clinical trials have been exploring this medication particularly for patients who don’t respond well to standard steroid therapy or who cannot tolerate steroids due to side effects.^[9]

Early results from smaller studies suggest rituximab can reduce the size of fibrotic masses and help patients avoid long-term steroid use. However, larger controlled trials are still needed to establish exactly which patients benefit most and what the optimal dosing schedule should be. Rituximab has a generally favorable safety profile compared to long-term steroids, though it does carry its own risks including increased infection susceptibility.^[11]

Understanding IgG4-Related Disease

An important discovery in recent years is that many cases of retroperitoneal fibrosis are actually part of a broader condition called IgG4-related disease. This is a systemic autoimmune disorder where the body produces too much of a specific type of antibody called immunoglobulin G4. This condition can affect multiple organs including the pancreas, salivary glands, thyroid, and retroperitoneum.^[6]

Recognizing when retroperitoneal fibrosis is part of IgG4-related disease is important because it may respond particularly well to certain treatments. Blood tests measuring IgG4 levels and tissue biopsies showing characteristic patterns of IgG4-positive cells help make this diagnosis. Clinical trials are specifically investigating treatments targeted at the mechanisms underlying IgG4-related disease, which could benefit many patients with retroperitoneal fibrosis.^[5]

Phase and Location of Clinical Trials

Clinical trials proceed through several phases. Phase I trials primarily test whether a new treatment is safe and determine appropriate doses. Phase II trials explore whether the treatment actually works in patients with the disease. Phase III trials compare the new treatment directly against current standard treatments to see if it offers advantages. Understanding these phases helps patients and doctors decide whether participating in a trial makes sense for a particular situation.^[2]

Clinical trials for rare diseases like retroperitoneal fibrosis often take place at major medical centers with expertise in the condition. These may be located throughout Europe, the United States, and other regions. Eligibility for trials typically depends on factors like disease stage, previous treatments tried, kidney function, and overall health status.^[11]

Patient Registries and Research

Because retroperitoneal fibrosis is so rare, patient registries play a crucial role in advancing understanding and treatment. The RaDaR Rare Disease Registry and similar databases collect information about patients’ symptoms, treatments, and outcomes over time. These registries help researchers identify patterns, compare different treatment approaches, and generate the evidence needed to improve care. Patients who participate in registries contribute valuable data even if they’re not enrolled in a specific drug trial.^[14]

Most Common Treatment Methods

• Corticosteroid Therapy
  • Prednisolone at 40-60 mg per day, tapered over 2-3 months to 10 mg daily
  • Treatment duration typically 12-24 months
  • Reduces fibrotic mass size by approximately 50% in up to 95% of cases
  • Successful outcomes in about 83% of patients
  • May be combined with other immunosuppressive agents
• Other Immunosuppressive Medications
  • Azathioprine used in combination with steroids, particularly when inflammation markers are elevated
  • Mycophenolate mofetil (MMF) reported to give better outcomes in some centers
  • Methotrexate, cyclophosphamide, and cyclosporine reserved for refractory cases
  • Used as steroid-sparing agents to reduce long-term steroid exposure
• Tamoxifen and Hormonal Treatments
  • Selective estrogen receptor modulator showing promise in small studies
  • Used alone or in combination with other medications
  • Particularly considered when patients cannot tolerate steroids
  • Medroxyprogesterone acetate and progesterone explored experimentally
• Surgical Interventions
  • Double J stent (DJ stent) placement to relieve ureter obstruction
  • Percutaneous nephrostomy (PCN) for direct kidney drainage
  • Ureterolysis to free ureters from fibrous tissue
  • Can be performed through open surgery or minimally invasive laparoscopy
  • Combining stent placement with medical therapy reduces re-narrowing from 48% to 10%
• Experimental and Trial Therapies
  • Rituximab targeting B cells in autoimmune processes
  • Treatments specifically for IgG4-related disease
  • Participation in patient registries like RaDaR to advance research
  • Clinical trials in various phases testing novel approaches

Combining Treatments and Long-Term Management

The most effective approach to retroperitoneal fibrosis usually involves combining different treatment strategies rather than relying on any single method. Optimal care requires an integrated approach where surgical interventions address immediate threats like ureter blockage, while medical therapy tackles the underlying inflammatory process driving tissue scarring.^[2]

Long-term monitoring remains essential even after successful initial treatment because the disease can reactivate. Patients typically need regular follow-up appointments that include blood tests checking kidney function and inflammatory markers, along with periodic imaging studies like CT scans or MRI to watch for any regrowth of fibrous tissue. This surveillance allows doctors to catch and treat recurrences early, before they cause serious complications.^[14]

Lifestyle modifications also play an important role in managing retroperitoneal fibrosis. For patients whose condition relates to blood vessel disease, adopting heart-healthy habits becomes especially important. This includes regular mild exercise, maintaining ideal body weight, avoiding tobacco products, and following a nutritious diet. These measures may help slow disease progression and improve overall health outcomes.^[14]

The choice of treatment should ultimately depend on multiple factors including the severity of disease, presence of complications, patient characteristics like age and other medical conditions, potential side effects of different therapies, and the expertise available at the treating medical center. A recent comprehensive analysis found no statistically significant differences in effectiveness between various treatment approaches for outcomes like regression of fibrosis and freedom from stents. This suggests that treatment decisions can be individualized based on each patient’s unique situation rather than following a rigid one-size-fits-all protocol.^[11]